Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours.

International journal of oncology - 1 Mar 2018

Chen Lindi, Esfandiari Arman, Reaves William, Vu Annette, Hogarty Michael D, Lunec John, Tweddle Deborah A

Abstract excerpt

Cell lines established from the TH-MYCN transgenic murine model of neuroblastoma are a valuable preclinical, immunocompetent, syngeneic model of neuroblastoma, for which knowledge of their p53 pathway status is important. In this study, the Trp53 status and functional response to Nutlin-3 and ionising radiation (IR) were determined in 6 adherent TH-MYCN transgenic cell lines using Sanger sequencing, western blot...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Imidazoles
Share to N-Myc Proto-Oncogene Protein

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Neuroblastoma

Share to Piperazines

Share to Proto-Oncogene Proteins c-mdm2

Share to Pyrrolidines

Share to Radiation, Ionizing

Share to Spiro Compounds

Source

Identifiers

PMID: 29393340
DOI: 10.3892/ijo.2018.4261

Genes

MYCN
MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours.PMID 29393340Read ↗

Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.Semantic proximity Read ↗

Mdm2 Deficiency Suppresses MYCN-Driven Neuroblastoma Tumorigenesis In VivoSemantic proximity Read ↗

Small-Molecule MDM2 Antagonists as a New Therapy Concept for NeuroblastomaSemantic proximity Read ↗

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.Semantic proximity Read ↗

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.Semantic proximity Read ↗

miRNA Expression Profiling of the Murine TH-MYCN Neuroblastoma Model Reveals Similarities with Human Tumors and Identifies Novel Candidate MiRNAsSemantic proximity Read ↗

Tumor Development, Growth Characteristics and Spectrum of Genetic Aberrations in the TH-MYCN Mouse Model of NeuroblastomaSemantic proximity Read ↗

Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastomaSemantic proximity Read ↗

p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting RadioresistanceSemantic proximity Read ↗

p53 determines multidrug sensitivity of childhood neuroblastoma.Semantic proximity Read ↗

A novel dysfunctional p53 mutation in the human neuroblastoma cell line TGW.Semantic proximity Read ↗

Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.